Assistant Professor of Neurology, Harvard Medical School and Mass General Brigham
Dr. Korecka-Roet is a neuroscientist dedicated to uncovering the earliest cellular changes that drive neurodegenerative diseases and translating those discoveries into new therapeutic strategies. Trained in the Netherlands, she earned her PhD at the Vrije University in Amsterdam, where she studied Parkinson’s disease and gene therapy approaches, followed by advanced postdoctoral work in patient-derived stem cell models and live-cell imaging at McLean Hospital, Harvard Medical School. Her research has contributed to the development of novel antisense oligonucleotide (ASO) therapies for Parkinson’s disease, targeting the LRRK2 pathway. Now an Assistant Professor of Neurology at Mass General Brigham/Harvard Medical School, Dr. Korecka leads a laboratory that builds patient stem cell-derived neuronal models to refine and de-risk genetic therapeutics for neurological disorders. Her lab investigates how early disruptions in neuronal activity and neuroimmune signaling contribute to disease, with current work spanning Parkinson’s disease and rare genetic ataxias such as DRPLA, AOA2, and SCA3. By combining patient-specific neurons and glial cells with advanced live-cell functional assays, her team evaluates ASO strategies, gene-editing approaches, and small-molecule therapies to identify interventions that can modify disease at its earliest stages.
Assistant Professor of Neurology, Harvard Medical School and Mass General Brigham
Dr. Korecka-Roet is a neuroscientist dedicated to uncovering the earliest cellular changes that drive neurodegenerative diseases and translating those discoveries into new therapeutic strategies. Trained in the Netherlands, she earned her PhD at the Vrije University in Amsterdam, where she studied Parkinson’s disease and gene therapy approaches, followed by advanced postdoctoral work in patient-derived stem cell models and live-cell imaging at McLean Hospital, Harvard Medical School. Her research has contributed to the development of novel antisense oligonucleotide (ASO) therapies for Parkinson’s disease, targeting the LRRK2 pathway. Now an Assistant Professor of Neurology at Mass General Brigham/Harvard Medical School, Dr. Korecka leads a laboratory that builds patient stem cell-derived neuronal models to refine and de-risk genetic therapeutics for neurological disorders. Her lab investigates how early disruptions in neuronal activity and neuroimmune signaling contribute to disease, with current work spanning Parkinson’s disease and rare genetic ataxias such as DRPLA, AOA2, and SCA3. By combining patient-specific neurons and glial cells with advanced live-cell functional assays, her team evaluates ASO strategies, gene-editing approaches, and small-molecule therapies to identify interventions that can modify disease at its earliest stages.